Cover Image
市場調查報告書

Reliance Life Sciences Pvt. Ltd.的產品平台分析

Reliance Life Sciences Pvt. Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 257881
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Reliance Life Sciences Pvt. Ltd.的產品平台分析 Reliance Life Sciences Pvt. Ltd. - Product Pipeline Review - 2016
出版日期: 2016年08月24日 內容資訊: 英文 35 Pages
簡介

Reliance Life Sciences Pvt. Ltd.是總公司在印度的生物科技企業,產業範圍跨生物製藥、製藥、再生醫藥品、臨床研究、分子診斷等多方面。

本報告提供Reliance Life Sciences Pvt. Ltd. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Reliance Life Sciences Pvt. Ltd. 的基本資料

  • Reliance Life Sciences Pvt. Ltd. 概要
  • 主要資訊
  • 企業資料

Reliance Life Sciences Pvt. Ltd. :R&D概要

  • 主要的治療範圍

Reliance Life Sciences Pvt. Ltd. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Reliance Life Sciences Pvt. Ltd. :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Reliance Life Sciences Pvt. Ltd.:藥物簡介

  • infliximab biosimilar
  • RTPR-013
  • RTPR-026
  • trastuzumab biosimilar
  • ReliDerm-DT
  • ReliDerm-M
  • RHSC-001
  • pegfilgrastim
  • RSCL-0520
  • Small Interference RNA for Undisclosed Indications
  • Flavanthridine
  • Monoclonal Antibodies for Oncology and Inflammation
  • Small Molecules for Inflammatory Disorders

Reliance Life Sciences Pvt. Ltd. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Reliance Life Sciences Pvt. Ltd. :現在暫停中的計劃

Reliance Life Sciences Pvt. Ltd. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08130CDB

Summary

Global Markets Direct's, 'Reliance Life Sciences Pvt. Ltd. - Product Pipeline Review - 2016', provides an overview of the Reliance Life Sciences Pvt. Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Reliance Life Sciences Pvt. Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Reliance Life Sciences Pvt. Ltd.
  • The report provides overview of Reliance Life Sciences Pvt. Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Reliance Life Sciences Pvt. Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Reliance Life Sciences Pvt. Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Reliance Life Sciences Pvt. Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Reliance Life Sciences Pvt. Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Reliance Life Sciences Pvt. Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Reliance Life Sciences Pvt. Ltd. Snapshot
    • Reliance Life Sciences Pvt. Ltd. Overview
    • Key Information
    • Key Facts
  • Reliance Life Sciences Pvt. Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products Glance
    • Reliance Life Sciences Pvt. Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Reliance Life Sciences Pvt. Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Reliance Life Sciences Pvt. Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Reliance Life Sciences Pvt. Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Reliance Life Sciences Pvt. Ltd. - Drug Profiles
    • cetuximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides for Undisclosed Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RSCL-0520
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Oncology and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RSCL-0521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NeuroRel
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Analysis
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products by Target
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products by Route of Administration
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products by Molecule Type
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products by Mechanism of Action
  • Reliance Life Sciences Pvt. Ltd. - Dormant Projects
  • Reliance Life Sciences Pvt. Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Reliance Life Sciences Pvt. Ltd., Key Information
  • Reliance Life Sciences Pvt. Ltd., Key Facts
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Indication, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Stage of Development, 2016
  • Reliance Life Sciences Pvt. Ltd. - Monotherapy Products in Pipeline, 2016
  • Reliance Life Sciences Pvt. Ltd. - Out-Licensed Products in Pipeline, 2016
  • Reliance Life Sciences Pvt. Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Reliance Life Sciences Pvt. Ltd. - Phase III, 2016
  • Reliance Life Sciences Pvt. Ltd. - Phase II, 2016
  • Reliance Life Sciences Pvt. Ltd. - Preclinical, 2016
  • Reliance Life Sciences Pvt. Ltd. - Discovery, 2016
  • Reliance Life Sciences Pvt. Ltd. - Unknown, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Target, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Route of Administration, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Molecule Type, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Reliance Life Sciences Pvt. Ltd. - Dormant Developmental Projects,2016
  • Reliance Life Sciences Pvt. Ltd., Other Locations
  • Reliance Life Sciences Pvt. Ltd., Subsidiaries

List of Figures

  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Indication, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Stage of Development, 2016
  • Reliance Life Sciences Pvt. Ltd. - Monotherapy Products in Pipeline, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Target, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Route of Administration, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline by Molecule Type, 2016
  • Reliance Life Sciences Pvt. Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top